FDA Grants Fast Track to Vir's VIR-5500 for Late-Line Prostate Cancer
VIR has more than doubled off its 52-week low of $4.815 on elevated volume (1.9× avg).
Summary
The FDA granted Fast Track designation to VIR-5500, Vir's PSMA-targeted dual-masked T-cell engager, for late-line metastatic castration-resistant prostate cancer. This regulatory milestone accelerates development and review, and the company plans to start pivotal Phase 3 trials in 2027. Phase 1 data reported earlier this year showed the drug was well tolerated with promising anti-tumor activity. The designation validates the program's potential in a high-unmet-need indication and strengthens the Astellas collaboration. With a $1.9B market cap and $1.01B cash, this is a meaningful pipeline advancement for a clinical-stage biotech.
At the time of this announcement, VIR was trading at $11.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $4.82 to $11.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.